Examination of the usefulness as the tumor marker of the NY-ESO-1 antibody titer in the stomach cancer patient

Examination of the usefulness as the tumor marker of the NY-ESO-1 antibody titer in the stomach cancer patient - Examination of the usefulness as the tumor marker of the NY-ESO-1 antibody titer in the stomach cancer patient

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007925

Enrollment

1000

Registered

2012-05-21

Start date

2012-05-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are diagnosed as gastric cancer which are proven by biopsy as adenocarinoma and can receive radical resection.

Exclusion criteria

Exclusion criteria: Synchronous or metachronous (within 5 years) malignancies

Design outcomes

Primary

Measure	Time frame
Recurrence prediction by the NY-ESO-1 antibody titer In the stomach cancer patients, with NY-ESO-1 antibody titer positive before surgery, that has been resected radically, NY-ESO-1 antibody titer was measured. We examine The recurrence rate of the NY-ESO-1 antibody-positive case of the first year after surgery.	—

Secondary

Measure	Time frame
1. NY-ESO-1 antibody titer positive rate 2. Incidence of the NY-ESO-1 antigen expression in the gastric cancer tissue 3. Correlation between NY-ESO-1 antibody titer and prognosis 4. Correlation between expression of the NY-ESO-1 antigen and prognosis 5. Relations withNY-ESO-1 antibody titer and the effect of the chemotherapy	—

Countries

Japan

Contacts

Public ContactKoji Tanaka

Osaka University Clinical Research Group for Gastroenterological Study Osaka University Clinical Research Group for Gastroenterological Study

ktanaka@gesurg.med.osaka-u.ac.jp06-6879-3251

Outcome results